↓ Skip to main content

Continuity of CVD treatment during the COVID-19 pandemic: evidence from East Java, Indonesia

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, March 2024
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
38 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Continuity of CVD treatment during the COVID-19 pandemic: evidence from East Java, Indonesia
Published in
Journal of Pharmaceutical Policy and Practice, March 2024
DOI 10.1186/s40545-022-00509-w
Pubmed ID
Authors

Aksari Dewi, Elizabeth Pisani, Bachtiar Rifai Pratita Ihsan, Ayuk Lawuningtyas Hariadini, Anushka Patel, Anna Palagyi, Devarsetty Praveen, Sujarwoto, Diana Lyrawati

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 38 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 3 8%
Student > Doctoral Student 3 8%
Student > Master 3 8%
Student > Bachelor 3 8%
Lecturer > Senior Lecturer 1 3%
Other 3 8%
Unknown 22 58%
Readers by discipline Count As %
Medicine and Dentistry 6 16%
Unspecified 3 8%
Nursing and Health Professions 2 5%
Mathematics 1 3%
Immunology and Microbiology 1 3%
Other 3 8%
Unknown 22 58%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2023.
All research outputs
#16,131,813
of 25,498,750 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#327
of 520 outputs
Outputs of similar age
#76,076
of 173,511 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#6
of 11 outputs
Altmetric has tracked 25,498,750 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 520 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 173,511 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.